Chinese Abstract

Chinese Abstract

Objective: This study conducts clinical observation and efficacy analysis of Professor Pei Zhengxue’s “Lanzhou Formula” combined with Western chemotherapy in patients with chronic myelogenous leukemia, and compares it with the group receiving Western chemotherapy alone. Based on changes in patients’ peripheral blood counts, bone marrow morphology, and clinical symptoms and signs, the study explores how Pei’s “Lanzhou Formula” enhances normal hematopoietic function of the bone marrow and improves clinical symptoms, as well as the underlying mechanisms. The aim is to provide sufficient scientific theoretical basis for its widespread clinical application.

Methods: Thirty patients were randomly divided into two groups: a control group (Western chemotherapy alone) and a treatment group (Lanzhou Formula combined with Western chemotherapy). At enrollment, there were no significant differences between the two groups in terms of age, gender, clinical symptoms and signs, blood counts, or degree of bone marrow hyperplasia, as determined by χ² test (P>0.05). After three months of treatment, the patients’ blood counts, bone marrow morphology, and clinical symptoms and signs were observed, and a comparative efficacy analysis was conducted between the two groups.

Results:

First, according to t-test (P<0.05), the time to disappearance of symptoms in the treatment group was significantly shorter than that in the control group. The disappearance rate, as determined by χ² test (P<0.05), also showed a significant increase in the treatment group compared with the control group.

Second, there was no significant difference in the changes of HGB, WBC, and PLT before and after treatment between the treatment group and the control group (P>0.05).

Third, the degree of malignant bone marrow hyperplasia decreased in the treatment group compared with the control group, and this difference was statistically significant (P<0.05).

Conclusion: This clinical study demonstrates that integrated traditional Chinese and Western medicine treatment has greater advantages than Western chemotherapy alone in improving symptoms and enhancing normal hematopoietic function of the bone marrow in patients with chronic myelogenous leukemia. It shows that Pei’s “Lanzhou Formula” can enhance normal bone marrow hematopoiesis and has a synergistic effect when used in conjunction with Western chemotherapy, providing a solid basis for the future clinical promotion and application of this formula.

Keywords: Pei Zhengxue, Lanzhou Formula, Chronic Myelogenous Leukemia